What is the current Injection Influenza Vaccine market size?

The Injection Influenza Vaccine market size is approximately USD 4.8 billion as of 2022.

What is the expected growth forecast for the Injection Influenza Vaccine market?

The market is expected to grow at a CAGR of 6.2% from 2023 to 2028, driven by increasing demand.

What are the key drivers of the Injection Influenza Vaccine market?

Key drivers include rising awareness, government initiatives, and technological advancements in vaccine development.

What are the major challenges facing the Injection Influenza Vaccine market?

Challenges include vaccine efficacy, supply chain disruptions, and stringent regulatory requirements.

Which regions are leading the Injection Influenza Vaccine market?

North America and Europe are the leading regions, accounting for over 60% of the market share.

Who are the top companies in the Injection Influenza Vaccine market?

Top companies include Sanofi, GSK, and Pfizer, which account for over 70% of the market share.

What future opportunities exist in the Injection Influenza Vaccine market?

Future opportunities include the development of universal influenza vaccines and increased adoption in emerging markets.

How is technology impacting the Injection Influenza Vaccine market?

Technological advancements in vaccine development, such as mRNA technology, are improving vaccine efficacy and safety.

What is the current regulatory landscape for the Injection Influenza Vaccine market?

The regulatory landscape is stringent, with vaccines requiring approval from authorities such as the FDA and EMA.

What is the future outlook for the Injection Influenza Vaccine market?

The future outlook is positive, with increasing demand and advancements in vaccine technology driving market growth.

Injection Influenza Vaccine Industry Trends & Competitive Analysis 2033

Injection Influenza Vaccine by Application (6 Months to 3 Years, > 3 Years), by Types (Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $4.2 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $4.2 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Injection Influenza Vaccine Market Overview

The Injection Influenza Vaccine market refers to the global market for vaccines administered through injection to protect against influenza. As the injection influenza vaccine market size continues to grow, driven by increasing demand for effective immunization against seasonal and pandemic influenza, the growth outlook for this market is promising, with a projected market forecast of significant expansion over the forecast period. The industry expansion is driven by advances in vaccine technology, growing awareness of the importance of vaccination, and rising investments in healthcare infrastructure. The scope of this market encompasses various types of influenza vaccines, including trivalent and quadrivalent vaccines, and covers applications across different demographics, including pediatric, adult, and geriatric populations.

Loading chart…

The current Injection Influenza Vaccine market size is approximately $5.5 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of around 7-8% over the forecast period. Key forces shaping the industry include technology shifts towards more effective and safer vaccine formulations, regulations governing vaccine approval and distribution, and changing consumer behavior driven by increasing awareness of health and wellness. The largest region for the injection influenza vaccine market is North America, while the fastest-growing region is expected to be Asia Pacific, driven by rising healthcare investments and growing demand for immunization. As the market continues to evolve, driven by these macro drivers, it is essential for stakeholders to stay informed about the latest trends and developments to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 million
Revenue forecast in 2033	7.66 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; CSL; GSK; Viatris; AstraZeneca; Hualan Bio; Changchun Institute of Biological; Sinovac; Jiangsu GDK; KM Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Injection Influenza Vaccine market is experiencing significant growth, driven by increasing demand for effective flu vaccines and advancements in vaccine technology. The Injection Influenza Vaccine market size is expected to expand substantially, with a growth forecast that indicates a notable increase in revenue over the next few years.

Growth Drivers2 items

Advances in vaccine technology, such as the development of quadrivalent vaccines, are driving growth in the Injection Influenza Vaccine market by providing enhanced protection against multiple flu strains.

Government initiatives and recommendations for annual flu vaccinations are also contributing to the growth of the Injection Influenza Vaccine market size, particularly in regions with high vaccination rates.

Restraints2 items

The high cost of developing and manufacturing Injection Influenza Vaccines, particularly for newer technologies like cell-based vaccines, is a significant restraint on the growth of the Injection Influenza Vaccine market.

Supply chain disruptions and logistics challenges, especially in regions with limited healthcare infrastructure, can limit the availability of Injection Influenza Vaccines and hinder market growth.

Opportunities2 items

The increasing demand for flu vaccines in emerging markets presents a significant opportunity for growth in the Injection Influenza Vaccine market, driven by expanding healthcare coverage and rising awareness of preventive care.

Partnerships and collaborations between vaccine manufacturers, research institutions, and healthcare organizations can facilitate the development of new and innovative Injection Influenza Vaccines, further driving market growth and expansion.

Challenges2 items

Vaccine hesitancy and misinformation about the safety and efficacy of Injection Influenza Vaccines can pose a challenge to market growth, particularly in regions with low vaccination rates and limited public health awareness.

The potential for antigenic drift and antigenic shift in flu viruses requires continuous monitoring and updating of Injection Influenza Vaccines, presenting a challenge for manufacturers to keep pace with evolving viral strains and maintain the effectiveness of their products.

Market Segmentation

Loading chart…

The Application segment of the Injection Influenza Vaccine market refers to the various uses of the vaccine, including pediatric and adult vaccinations. This segment contributes significantly to the overall market size, as it directly affects the demand for the vaccine. The application segment is further divided into subtypes, such as seasonal and pandemic influenza vaccinations, which cater to different demographic needs. Understanding the Injection Influenza Vaccine segmentation is crucial for market players to develop targeted strategies and capitalize on emerging trends.

The Types segment of the Injection Influenza Vaccine market encompasses various vaccine formulations, including trivalent and quadrivalent influenza vaccines. This segment plays a vital role in determining the market size, as different types of vaccines cater to distinct patient needs and preferences. The types segment is also divided into subtypes, such as inactivated and live attenuated vaccines, which vary in their composition and administration. Analyzing the market taxonomy of the Injection Influenza Vaccine industry helps stakeholders identify opportunities for growth and development in specific segments.

Injection Influenza Vaccine Segmentation Breakdown6 items

Application

6 Months to 3 Years

> 3 Years

Types

Trivalent Influenza Vaccine

Quadrivalent Influenza Vaccine

Regional Insights

Loading chart…

The Injection Influenza Vaccine market growth is expected to vary across regions, with the largest share held by North America, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of vaccination programs, government policies supporting immunization, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America - high ecosystem maturity, established infrastructure, and strong demographics; Europe - favorable policies, rising adoption, and growing investments; Asia Pacific - large demographics, increasing adoption, and improving infrastructure; Latin America - expanding ecosystem, growing investments, and rising adoption; Middle East & Africa - developing infrastructure, increasing adoption, and government-supported policies.

The regional forecast indicates that the Injection Influenza Vaccine market will experience significant growth, driven by factors such as increasing demand for vaccination, advancements in technology, and expanding distribution networks. Understanding these regional dynamics is crucial for stakeholders to navigate the complex Injection Influenza Vaccine market and capitalize on emerging opportunities.

Competitive Landscape

The Injection Influenza Vaccine market is moderately consolidated, with a mix of global players and local companies competing for market share. The Injection Influenza Vaccine competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to dominate the market, but local companies are gaining traction through strategic partnerships and regional expansion.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Common competitive differentiators include technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting to these challenges by focusing on specific strategic initiatives, as outlined below:

Sanofi: regional expansion

CSL: innovation pipeline

GSK: premium pricing

Viatris: OEM tie-ups

AstraZeneca: vertical integration

Hualan Bio: local manufacturing

Key Injection Influenza Vaccine Companies10 items

Sanofi

CSL

GSK

Viatris

AstraZeneca

Hualan Bio

Changchun Institute of Biological

Sinovac

Jiangsu GDK

KM Biologics

Market Ecosystem

The Injection Influenza Vaccine ecosystem spans upstream, midstream, and downstream activities, encompassing technology providers, integrators, channels, and end users. Value is created and captured as raw materials and components are transformed into vaccines, which are then distributed to healthcare providers and administered to patients. The ecosystem's boundaries are defined by the interactions among these participants, influencing the development, production, and delivery of injection influenza vaccines.

Raw material suppliers — provide key vaccine components

OEMs / manufacturers — produce injection influenza vaccines

Distributors / channel partners — deliver vaccines to healthcare providers

Service providers / after-sales — offer support and training for vaccine administration

End users / buyers — healthcare providers and patients

Regulators/standards bodies — oversee vaccine safety and efficacy

Data/analytics providers — track vaccine distribution and efficacy

In the Injection Influenza Vaccine ecosystem, value flows through the interactions among participants, with control points influencing adoption, such as regulatory approvals and reimbursement policies. Dependency risks, including input constraints and standards compliance, can impact vaccine production and distribution. Switching costs and partnerships between manufacturers and distributors can also affect the ecosystem's dynamics. Furthermore, the ecosystem may differ by region due to varying regulatory requirements and healthcare infrastructure, highlighting the need for a nuanced value chain analysis to understand the complex relationships within the Injection Influenza Vaccine ecosystem.

Recent Industry Insights

The Injection Influenza Vaccine industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies have led to the creation of new vaccine formulations and enhanced production capabilities. Notable mergers and acquisitions have also taken place, resulting in increased market consolidation and expanded product portfolios. Furthermore, several product launches have occurred, featuring innovative technologies such as cell-based and recombinant vaccines, which offer improved efficacy and safety profiles. Regulatory changes, including updated guidelines for vaccine approval and labeling, have also impacted the industry. These developments are expected to shape the future of the injection influenza vaccine market, influencing consumer and enterprise trends, and driving funding rounds or expansions in the sector.

Analyst Overview

As the Lead Analyst, I provide an expert view on the Injection Influenza Vaccine market. The market attractiveness is high due to the increasing demand for influenza vaccines, driven by the rising awareness of infectious diseases and government initiatives to prevent outbreaks. The competitive intensity is moderate, with key players dominating the market, but new entrants are expected to increase competition. The long-term outlook for the Injection Influenza Vaccine market outlook is positive, driven by innovations in vaccine development and improvements in distribution channels. However, key risk factors include supply chain disruptions and regulatory changes. The demand–supply balance is expected to be stable, with manufacturers increasing production to meet growing demand.

11 items

1. Executive Summary

2. Injection Influenza Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Injection Influenza Vaccine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Injection Influenza Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. 6 Months to 3 Years

6.1.2. > 3 Years

6.2. Global Injection Influenza Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Trivalent Influenza Vaccine

6.2.2. Quadrivalent Influenza Vaccine

6.3. Global Injection Influenza Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Injection Influenza Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Injection Influenza Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Injection Influenza Vaccine Market Competition by Key Manufacturers

8.1. Global Injection Influenza Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Injection Influenza Vaccine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sanofi

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. CSL

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GSK

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Viatris

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AstraZeneca

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hualan Bio

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Changchun Institute of Biological

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sinovac

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Jiangsu GDK

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. KM Biologics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Injection Influenza Vaccine Market

Figure 4: Global Injection Influenza Vaccine Market: Drivers

Figure 5: Global Injection Influenza Vaccine Market: Challenges

Figure 6: Global Injection Influenza Vaccine Market: Trends

Figure 7: Global Injection Influenza Vaccine Market: Opportunity

Figure 8: Global Injection Influenza Vaccine Market: Restraint

Figure 9: Global Injection Influenza Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Injection Influenza Vaccine Market Value (USD Million) By Region

Figure 15: Global Injection Influenza Vaccine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Injection Influenza Vaccine Market Value (USD Million) By Region

Figure 23: Global Injection Influenza Vaccine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Injection Influenza Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Injection Influenza Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Injection Influenza Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Injection Influenza Vaccine Market Value (USD Million) By Region

Table 10: Global Injection Influenza Vaccine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Injection Influenza Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Injection Influenza Vaccine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Injection Influenza Vaccine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sanofi Basic Information And Sales Area

Table 31: Sanofi. Products Portfolio

Table 32: CSL Basic Information And Sales Area

Table 33: CSL. Products Portfolio

Table 34: GSK Basic Information And Sales Area

Table 35: GSK. Products Portfolio

Table 36: Viatris Basic Information And Sales Area

Table 37: Viatris. Products Portfolio

Table 38: AstraZeneca Basic Information And Sales Area

Table 39: AstraZeneca. Products Portfolio

Table 40: Hualan Bio Basic Information And Sales Area

Table 41: Hualan Bio. Products Portfolio

Table 42: Changchun Institute of Biological Basic Information And Sales Area

Table 43: Changchun Institute of Biological. Products Portfolio

Table 44: Sinovac Basic Information And Sales Area

Table 45: Sinovac. Products Portfolio

Table 46: Jiangsu GDK Basic Information And Sales Area

Table 47: Jiangsu GDK. Products Portfolio

Table 48: KM Biologics Basic Information And Sales Area

Table 49: KM Biologics. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Injection Influenza Vaccine Market Value (USD Million) By Region

Table 55: Global Injection Influenza Vaccine Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Injection Influenza Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 million
Revenue forecast in 2033	7.66 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; CSL; GSK; Viatris; AstraZeneca; Hualan Bio; Changchun Institute of Biological; Sinovac; Jiangsu GDK; KM Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Supply chain disruptions and logistics challenges, especially in regions with limited healthcare infrastructure, can limit the availability of Injection Influenza Vaccines and hinder market growth.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Injection Influenza Vaccine Segmentation Breakdown6 items

Application

6 Months to 3 Years

> 3 Years

Types

Trivalent Influenza Vaccine

Quadrivalent Influenza Vaccine

Regional Insights

Loading chart…

Competitive Landscape

Sanofi: regional expansion

CSL: innovation pipeline

GSK: premium pricing

Viatris: OEM tie-ups

AstraZeneca: vertical integration

Hualan Bio: local manufacturing

Key Injection Influenza Vaccine Companies10 items

Sanofi

CSL

GSK

Viatris

AstraZeneca

Hualan Bio

Changchun Institute of Biological

Sinovac

Jiangsu GDK

KM Biologics

Market Ecosystem

Raw material suppliers — provide key vaccine components

OEMs / manufacturers — produce injection influenza vaccines

Distributors / channel partners — deliver vaccines to healthcare providers

Service providers / after-sales — offer support and training for vaccine administration

End users / buyers — healthcare providers and patients

Regulators/standards bodies — oversee vaccine safety and efficacy

Data/analytics providers — track vaccine distribution and efficacy

Recent Industry Insights

Analyst Overview

Table of Contents